• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Antigen in the Blood as a Diagnostic Test for In

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2022 Oct 22;9(11):ofac563.
doi: 10.1093/ofid/ofac563. eCollection 2022 Nov.
Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Antigen in the Blood as a Diagnostic Test for Infection and Infectious Viral Shedding


Sujata Mathur[SUP] 1 2 3 [/SUP], Michelle C Davidson[SUP] 3 4 [/SUP], Khamal Anglin[SUP] 2 3 [/SUP], Scott Lu[SUP] 1 2 3 [/SUP], Sarah A Goldberg[SUP] 1 2 3 [/SUP], Miguel Garcia-Knight[SUP] 5 [/SUP], Michel Tassetto[SUP] 5 [/SUP], Amethyst Zhang[SUP] 5 [/SUP], Mariela Romero[SUP] 2 3 [/SUP], Jesus Pineda-Ramirez[SUP] 2 3 [/SUP], Ruth Diaz-Sanchez[SUP] 2 3 [/SUP], Paulina Rugart[SUP] 2 3 [/SUP], Jessica Y Chen[SUP] 2 3 [/SUP], Kevin Donohue[SUP] 4 [/SUP], Joshua R Shak[SUP] 6 [/SUP], Ahmed Chenna[SUP] 7 [/SUP], John W Winslow[SUP] 7 [/SUP], Christos J Petropoulos[SUP] 7 [/SUP], Brandon C Yee[SUP] 7 [/SUP], Jeremy Lambert[SUP] 8 [/SUP], David V Glidden[SUP] 1 [/SUP], George W Rutherford[SUP] 1 2 [/SUP], Steven G Deeks[SUP] 9 [/SUP], Michael J Peluso[SUP] 9 [/SUP], Raul Andino[SUP] 5 [/SUP], Jeffrey N Martin[SUP] 1 [/SUP], J Daniel Kelly[SUP] 1 2 3 6 [/SUP]



Affiliations

Abstract

Background: SARS-CoV-2 nucleocapsid antigen can be detected in plasma, but little is known about its performance as a diagnostic test for acute SARS-CoV-2 infection or infectious viral shedding among nonhospitalized individuals.
Methods: We used data generated from anterior nasal and blood samples collected in a longitudinal household cohort of SARS-CoV-2 cases and contacts. Participants were classified as true positives if polymerase chain reaction (PCR) positive for SARS-CoV-2 and as true negatives if PCR negative and seronegative. Infectious viral shedding was determined by the cytopathic effect from viral culture. Stratified by 7 days after symptom onset, we constructed receiver operating characteristic (ROC) curves to describe optimized accuracy (Youden index), optimized sensitivity, and specificity.
Results: Of 80 participants, 58 (73%) were true positives while 22 (27%) were true negatives. Using the manufacturer's cutoff of 1.25 pg/mL for evaluating infection, sensitivity was higher from 0 to 7 days (77.6% [95% confidence interval {CI}, 64%-88.2%]) than from 8 to 14 days (43.2% [95% CI, 31.1%-54.5%]) after symptom onset; specificity was unchanged at 100% (95% CI, 88.1%-100%). This test had higher sensitivity (100% [95% CI, 88.4%-100%]) and lower specificity (65% [95% CI, 40.8%-84.6%]) for infectious viral shedding as compared with infection, particularly within the first week of symptom onset. Although the presence of N-antigen correlated with infectious viral shedding (r = 0.63; P < .01), sensitivity still declined over time. Additional cutoffs from ROC curves were identified to optimize sensitivity and specificity.
Conclusions: We found that this SARS-CoV-2 N-antigen test was highly sensitive for detecting early but not late infectious viral shedding, making it a viable screening test for community-dwelling individuals to inform isolation practices.

Keywords: blood; infectiousness; infectivity; nucleocapsid antigen; performance.
 
Back
Top Bottom